Webster Bank N. A. Sells 2,152 Shares of Johnson & Johnson (NYSE:JNJ)

Webster Bank N. A. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,566 shares of the company’s stock after selling 2,152 shares during the quarter. Webster Bank N. A.’s holdings in Johnson & Johnson were worth $7,391,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Tallon Kerry Patrick bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $290,000. Capital & Planning LLC boosted its position in shares of Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares in the last quarter. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Stablepoint Partners LLC boosted its position in shares of Johnson & Johnson by 1.1% during the 4th quarter. Stablepoint Partners LLC now owns 33,465 shares of the company’s stock worth $4,840,000 after purchasing an additional 371 shares in the last quarter. Finally, ETF Portfolio Partners Inc. boosted its position in shares of Johnson & Johnson by 7.1% during the 4th quarter. ETF Portfolio Partners Inc. now owns 1,779 shares of the company’s stock worth $257,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.7%

NYSE:JNJ opened at $153.44 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $369.19 billion, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a 50-day moving average price of $154.43 and a two-hundred day moving average price of $153.63.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.39%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on JNJ. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.